Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss

Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss

Don't be fooled by Regeneron Pharmaceuticals' (NASDAQ: REGN) year-to-date stock performance. The big biotech's shares might not have done much in 2021, but Regeneron has chalked up several big achievements. Just how much more was evident when Regeneron announced its first-quarter results before the market opened today.